| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.096 | 0.005 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.081 | 0.006 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | 0.09 | 0.006 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.007 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | -0.089 | 0.007 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.15 | 0.009 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | -0.082 | 0.01 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.12 | 0.01 |